3 month response in heavily pretreated patients = success in oncology.
When you can add a 3 month durable response benefit, to a heavily pretreated patient population who have relapsed, you call that a major success. SGI-110 looks very effective, and this is great news for the expansion trial.
Indeed it's excellent news for Astex. Unfortunately we just have a down day in the market, biotechs included. No worries though, I used it as a chance to buy additional shares at a discount. I feel even more confident doing so given the news. I expect some interesting price action next week.